Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival

Journal of Thoracic Oncology

Volumn 6, Issue 11, 2011, Pages 1793-1800

  Liu, Li ^a   Wu, Chen ^b   Wang, Ying ^a   Zhong, Rong ^a   Duan, Shengyu ^a   Wei, Sheng ^a   Lin, Songyi ^a   Zhang, Xinyu ^c   Tan, Wen ^b   Yu, Dianke ^b   Nie, Shaofa ^a   Miao, Xiaoping ^a   Lin, Dongxin ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b CANCER HOSPITAL   (China)

^c TSINGHUA UNIVERSITY   (China)

Author keywords

MDM2; Non small cell lung cancer; P53; P73; Survival

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; NAVELBINE; OXALIPLATIN; PROTEIN MDM2; PROTEIN P53; PROTEIN P73;

ADULT; ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

EID: 80054899523     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182272273     Document Type: Article

References (44)

1. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008;26:4617-4625.
2. Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594. (Pubitemid 351720831)
3. Coate LE, John T, Tsao MS, et al. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009;10:1001-1010.
4. Ahmad S. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes. Chem Biodivers 2010;7:543-566.
5. Hrstka R, Coates PJ, Vojtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009;13:440-453.
6. Dumont P, Leu JI, Della Pietra AC III, et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-365. (Pubitemid 36278852)
7. Muller M, Schleithoff ES, Stremmel W, et al. One, two, three-p53, p63, p73 and chemosensitivity. Drug Resist Updat 2006;9:288-306.
8. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402. (Pubitemid 38340307)
9. Leong CO, Vidnovic N, DeYoung MP, et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007;117:1370-1380. (Pubitemid 46718425)
10. Nomoto S, Haruki N, Kondo M, et al. Search for mutations and examination of allelic expression imbalance of the p73 gene at 1p36.33 in human lung cancers. Cancer Res 1998;58:1380-1383. (Pubitemid 28193594)
11. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997;90:809-819. (Pubitemid 27357971)
12. Li G, Wang LE, Chamberlain RM, et al. p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. Cancer Res 2004;64:6863-6866. (Pubitemid 39330992)
13. Jun HJ, Park SH, Lee WK, et al. Combined effects of p73 and MDM2 polymorphisms on the risk of lung cancer. Mol Carcinog 2007;46:100-105.
14. Schabath MB, Wu X, Wei Q, et al. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:158-161.
15. Grochola LF, Zeron-Medina J, Meriaux S, et al. Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Per-spect Biol 2010;2:a001032.
16. Vazquez A, Bond EE, Levine AJ, et al. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008;7:979-987.
17. Rayburn E, Zhang R, He J, et al. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 2005;5:27-41. (Pubitemid 40321798)
18. Strazisar M, Mlakar V, Glavac D. The expression of COX-2, hTERT, MDM2, LATS2 and S100A2 in different types of non-small cell lung cancer (NSCLC). Cell Mol Biol Lett 2009;14:442-456.
19. Heist RS, Zhou W, Chirieac LR, et al. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol 2007;25:2243-2247. (Pubitemid 46954650)
20. Bond GL, Hu W, Bond EE, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004;119:591-602. (Pubitemid 39535748)
21. Bond GL, Hu W, Levine A. A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res 2005;65:5481-5484. (Pubitemid 40911143)
22. Kulkarni DA, Vazquez A, Haffty BG, et al. A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis 2009;30:1910-1915.
23. Zhang X, Miao X, Guo Y, et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 2006;27:110-117. (Pubitemid 43042973)
24. Yuan P, Miao XP, Zhang XM, et al. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms]. Zhonghua Zhong Liu Za Zhi 2006; 28:107-110.
25. Viktorsson K, De Petris L, Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005;331: 868-880. (Pubitemid 40615518)
26. Huang ZH, Hua D, Du X. Polymorphisms in p53, GSTP1 and XRCC1 predict relapse and survival of gastric cancer patients treated with oxaliplatin-based adjuvant chemotherapy. Cancer Chemother Pharmacol 2009;64:1001-1007.
27. Toffoli G, Biason P, Russo A, et al. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res 2009;15:3550-3556.
28. Toyama T, Zhang Z, Nishio M, et al. Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients. Breast Cancer Res 2007;9:R34.
29. Chen J, Li D, Killary AM, et al. Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation. Ann Surg Oncol 2009;16: 431-439.
30. Yamasaki M, Miyata H, Fujiwara Y, et al. p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol 2010;17:634-642.
31. Han JY, Lee GK, Jang DH, et al. Association of p53 codon 72 polymorphism and MDM2 SNP309 with clinical outcome of advanced nonsmall cell lung cancer. Cancer 2008;113:799-807.
32. Chua HW, Ng D, Choo S, et al. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore. BMC Cancer 2010;10:88.
33. Matakidou A, El Galta R, Webb EL, et al. Lack of evidence that p53 Arg72Pro influences lung cancer prognosis: an analysis of survival in 619 female patients. Lung Cancer 2007;57:207-212. (Pubitemid 47043181)
34. Sullivan A, Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene 2004;23:3328-3337. (Pubitemid 38669822)
35. Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis 2005;26:103-107. (Pubitemid 40207704)
36. Li H, Yao L, Ouyang T, et al. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 2007;28:372-377. (Pubitemid 46321853)
37. Tokuchi Y, Hashimoto T, Kobayashi Y, et al. The expression of p73 is increased in lung cancer, independent of p53 gene alteration. Br J Cancer 1999;80:1623-1629. (Pubitemid 29308646)
38. Chien WP, Wong RH, Cheng YW, et al. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors. Ann Surg Oncol 2010;17:1194-1202.
39. Dong J, Ren B, Hu Z, et al. MDM2 SNP309 contributes to non-small cell lung cancer survival in Chinese. Mol Carcinog 2011;50:433-438.
40. Righetti SC, Perego P, Carenini N, et al. Cooperation between p53 and p73 in cisplatin-induced apoptosis in ovarian carcinoma cells. Cancer Lett 2008;263:140-144.
41. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009;9:749-758.
42. Yang M, Guo Y, Zhang X, et al. Interaction of P53 Arg72Pro and MDM2 T309G polymorphisms and their associations with risk of gastric cardia cancer. Carcinogenesis 2007;28:1996-2001. (Pubitemid 47500614)
43. Lohrum MA, Vousden KH. Regulation and function of the p53-related proteins: same family, different rules. Trends Cell Biol 2000;10:197-202. (Pubitemid 30193269)
44. Wang XQ, Ongkeko WM, Lau AW, et al. A possible role of p73 on the modulation of p53 level through MDM2. Cancer Res 2001;61:1598-1603. (Pubitemid 34292593)